构建与ubiquitination相关的风险模型,用于预测肺腺癌的预后
Dawei Sun1,2,3,4, Xiaohong Duan1,2,3, Ning Li1,2,3
1School of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University, No. 92 Weijin Road, Nankai District, Tianjin, 300072, China.
Scientific reports
|April 6, 2025
概括
这项研究确定了与ubiquitination相关的基因特征 (URRS) 作为肺腺癌的预后生物标志物. 较高的URRS表明更糟糕的预后和瘤微环境的改变,有助于治疗决策.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肺腺癌 (LUAD) 是最常见的肺癌类型.
- 作为一个关键的翻译后修饰,ubiquitination在癌症的发展和进展中起着重要作用.
- 了解在LUAD中无处不在的作用对于改善患者的治疗结果至关重要.
研究的目的:
- 为了调查ubiquitination和肺腺癌之间的关联.
- 开发一种新的与ubiquitination相关的基因特征 (URRS),用于预测LUAD预后.
- 探索URRS与瘤生物学特征之间的相关性,包括免疫透和化疗反应.
主要方法:
- 使用TCGA-LUAD队列进行培训和6个外部队列进行验证.
- 采用无监督聚类,考克斯回归,随机生存森林和LASSO考克斯回归来识别与普遍存在相关的基因 (URG).
- 根据基因表达计算URRS并评估其与预后,免疫透,瘤突变负担 (TMB),瘤新抗原负载 (TNB),PD1/L1表达和药物敏感性的相关性.
主要成果:
- 一个四个基因签名 (DTL,UBE2S,CISH,STC1) 被确定,形成了URRS.
- 较高的URRS与LUAD患者的预后较差显著相关 (HR=0.54,p<0.001),在外部队列中得到验证.
- 高URRS组表现出增加的PD1/L1表达,TMB,TNB和瘤微环境 (TME) 评分,对化疗药物的敏感性较低.
结论:
- 开发的基于ubiquitination的签名 (URRS) 作为肺腺癌的强有力的预后生物标志物.
- URRS可以帮助评估生物特征,预测治疗反应,并为LUAD患者指导治疗策略.
- 这种特征为肺腺癌管理提供了个性化医疗方法的潜力.
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
02:04Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K